Stem Cells and Regenerative Medicine Section, University College London, London, United Kingdom.
NIHR Great Ormond Street Hospital Biomedical Research Centre, UCL Great Ormond Street Institute of Child Health, University College London, London, United Kingdom.
Stem Cells. 2018 May;36(5):709-722. doi: 10.1002/stem.2775. Epub 2018 Feb 1.
Loss of photoreceptor cells due to retinal degeneration is one of the main causes of blindness in the developed world. Although there is currently no effective treatment, cell replacement therapy using stem-cell-derived photoreceptor cells may be a feasible future treatment option. In order to ensure safety and efficacy of this approach, robust cell isolation and purification protocols must be developed. To this end, we previously developed a biomarker panel for the isolation of mouse photoreceptor precursors from the developing mouse retina and mouse embryonic stem cell cultures. In the current study we applied this approach to the human pluripotent stem cell (hPSC) system, and identified novel biomarker combinations that can be leveraged for the isolation of human photoreceptors. Human retinal samples and hPSC-derived retinal organoid cultures were screened against 242 human monoclonal antibodies using a high through-put flow cytometry approach. We identified 46 biomarkers with significant expression levels in the human retina and hPSC differentiation cultures. Human retinal cell samples, either from fetal tissue or derived from embryonic and induced pluripotent stem cell cultures, were fluorescence-activated cell sorted (FACS) using selected candidate biomarkers that showed expression in discrete cell populations. Enrichment for photoreceptors and exclusion of mitotically active cells was demonstrated by immunocytochemical analysis with photoreceptor-specific antibodies and Ki-67. We established a biomarker combination, which enables the robust purification of viable human photoreceptors from both human retinae and hPSC-derived organoid cultures. Stem Cells 2018;36:709-722.
由于视网膜变性导致的光感受器细胞丧失是发达国家失明的主要原因之一。虽然目前尚无有效的治疗方法,但利用干细胞衍生的光感受器细胞进行细胞替代疗法可能是一种可行的未来治疗选择。为了确保这种方法的安全性和有效性,必须开发出强大的细胞分离和纯化方案。为此,我们之前开发了一种生物标志物面板,用于从发育中的小鼠视网膜和小鼠胚胎干细胞培养物中分离小鼠光感受器前体细胞。在当前的研究中,我们将这种方法应用于人类多能干细胞(hPSC)系统,并确定了新的生物标志物组合,可以用于分离人类光感受器。使用高通量流式细胞术筛选了 242 个人类单克隆抗体对人类视网膜样本和 hPSC 衍生的视网膜类器官培养物进行了筛选。我们确定了 46 种在人视网膜和 hPSC 分化培养物中具有显著表达水平的生物标志物。使用在离散细胞群体中表达的选定候选生物标志物,通过荧光激活细胞分选(FACS)对来自胎儿组织或胚胎和诱导多能干细胞培养物的人类视网膜细胞样本进行分选。免疫细胞化学分析显示,用光感受器特异性抗体和 Ki-67 对光感受器进行了富集,排除了有丝分裂活性细胞。我们建立了一种生物标志物组合,可从人视网膜和 hPSC 衍生的类器官培养物中强大地纯化出有活力的人类光感受器。干细胞 2018;36:709-722。